logo-loader
viewSummit Therapeutics PLC

Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress

Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress

Summit Therapeutics plc 
(‘Summit’ or the ‘Company’)

Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress

Oxford, UK, and Cambridge, MA, US, 6 November 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that management will participate in two panel sessions at the World Antimicrobial Resistance Congress, taking place 7-8 November 2019 in Washington, DC.

In the panel sessions, Dr David Roblin, Chief Operating Officer and President of R&D, Dr Richard Vickers, Chief Scientific Officer, and Dr David Powell, Head of Research, will highlight the potential benefits of developing new mechanistic classes of precision antibiotics, including potency against resistant and non-resistant bacteria with minimal disturbance to the gut microbiome. This supports the principles of antibiotic stewardship.

Details of the sessions:
Date: 7 November 2019
Time: 2:10pm EST
Session: Roundtable 3 Innovation & Stewardship – Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship

Date: 8 November 2019
Time: 1:00pm EST
Session: C-Suite Keynote Panel: Balancing continued innovation in R&D while navigating funding, stewardship and the overall commercial landscape

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit  
Glyn Edwards / Richard Pye (UK office)Tel:44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
   
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson  
   
N+1 Singer (Joint Broker)Tel:+44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking
  
   
Bryan Garnier & Co Limited (Joint Broker)Tel:+44 (0)20 7332 2500
Phil Walker / Dominic Wilson

 
  
MSL Group (US)Tel:+1 781 684 6652
Erin Anthoine [email protected]
   
Consilium Strategic Communications (UK)Tel:+44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Sukaina Virji [email protected]
Lindsey Neville  

-END-

Quick facts: Summit Therapeutics PLC

Price: 20.65

Market: AIM
Market Cap: £33.14 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

6 days, 18 hours ago